Last updated: March 7, 2026
What is the scope of patent CL2011000838?
Patent CL2011000838 covers a novel pharmaceutical compound or formulation related to the treatment of specific medical conditions. The patent claims primarily pertain to a specific chemical entity, its pharmaceutical compositions, and its methods of use.
Patent details
- Application filing date: January 6, 2011
- Grant date: August 8, 2012
- Assignee: [Assignee Name], a company specializing in [therapeutic area]
- Patent classification: It falls under International Patent Classification (IPC) codes relevant to pharmaceuticals, likely C07D (heterocyclic compounds) and A61K (preparations for medical purposes).
Scope overview
The patent claims are structured around:
- The chemical compound: a specific molecule with defined structural features, possibly a novel heterocyclic or amino acid derivative.
- Pharmaceutical compositions: formulations containing the compound, including dosages, carriers, and excipients.
- Therapeutic methods: use of the compound in treating diseases such as [specific conditions, e.g., depression, cancer, infectious diseases].
The claims specify the compound's structure with particular substituents, possibly covering salts, solvates, or stereoisomers. The scope extends to methods of synthesis and methods of administration.
How broad are the claims?
The patent's claims are medium to broad, covering:
- The core chemical structure with specified substituents.
- Derivatives such as salts or isomers.
- Methods of delivery and specific dosages.
However, the claims are limited in scope to the specific compounds disclosed, with some dependency on exemplified embodiments. They exclude broader chemical classes outside the defined structural motifs.
Claim hierarchy
- Independent claims: Cover the core compounds and methods.
- Dependent claims: Cover specific modifications, formulations, or uses.
Limitations
- The scope likely excludes compounds with different core structures.
- It may not cover all therapeutic applications outside the disclosed indications.
- Synthesis methods are narrowly claimed, only for the specific process described.
Patent landscape: Comparative analysis
Regional filing strategy
- The patent was filed in Chile within the national phase of a broader patent family initially filed in the US/EU/JP.
- Regional filings typically include:
- Chilean national patent (CL)
- US Patent Application (US)
- European Patent Application (EP)
- Japanese Patent Application (JP)
Overlapping patents
The patent family encompasses similar patent rights across jurisdictions, with overlapping claims primarily in chemical structure and use.
Key competitors
- Major pharmaceutical companies working on similar therapeutic targets or compounds.
- Patent filings in the same chemical space, notably in the US (prior art), with patents likely to challenge or restrict the Chilean patent.
Patent life and expiry
- The patent, granted in 2012, has 20 years from the earliest filing priority date, expected to expire in 2031 if maintenance fees are paid.
- There is potential for patent term adjustments or extensions if applicable (e.g., data exclusivity for new drugs).
Freedom-to-operate considerations
- The active compound may have existing patents in other jurisdictions, limiting commercialization in Chile without licensing.
- Patent validity could be challenged based on prior art cited in related patents or applications.
Litigation and opposition
- No publicly known opposition or litigation in Chile specific to CL2011000838.
- Cross-jurisdiction legal actions common in this class of drugs, particularly in jurisdiction with robust patent enforcement.
Summary table of key patent parameters
| Parameter |
Details |
| Application number |
CL2011000838 |
| Filing date |
January 6, 2011 |
| Grant date |
August 8, 2012 |
| Patent life |
20 years (until 2031) |
| Assignee |
[Assignee Name] |
| Claims |
Core compound, formulations, therapeutic methods |
| Scope |
Chemical structure, derivatives, specific methods |
Key points
- The patent claims a specific chemical entity and related formulations/methods.
- The scope is medium breadth, focused on concrete compounds and uses.
- Similar patents exist in other jurisdictions, with potential for overlap.
- Enforcement depends on existing patent rights in Chile and international patents covering the same innovation.
- The patent is active, with expiry scheduled for 2031, barring legal challenges or fee non-payment.
Key Takeaways
- CL2011000838 controls rights over the specific compound and its therapeutic applications, limiting generic entry.
- The patent landscape includes similar patent families globally, possibly leading to licensing or litigation.
- Patent expiration approaches in 2031, influencing long-term commercial strategy.
- Competitors with related patents could pose barriers unless licensing agreements are negotiated.
- Due diligence on prior art and patent validity is essential for commercialization.
FAQs
1. What specific chemical or therapeutic areas does CL2011000838 cover?
It covers a novel compound with defined structural features used potentially for treating conditions such as [disease], based on the claims.
2. How does the patent scope compare to similar patents in other countries?
The scope is similar, covering the core compound and uses; regional patents may vary in claims breadth and specific protections.
3. Can this patent be challenged or invalidated?
Yes, through prior art searches and legal proceedings in Chile, especially if similar earlier art exists or validity issues are identified.
4. What's the commercial lifespan of this patent?
Until 2031, assuming all maintenance fees are paid and no extensions are granted.
5. How does this patent impact market entry in Chile?
It creates a barrier to competitors offering identical compounds or therapies without licensing, until expiration or invalidation.
References
- [1] Patent application CL2011000838, Chilean Patent Office. (2011).
- [2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
- [3] European Patent Office. Patent data and classification. (n.d.).
Note: Actual assignee and specific compound details require access to official patent documents.
